Semler Scientific (SMLR) to Release Quarterly Earnings on Monday

Semler Scientific (NASDAQ:SMLR) is projected to issue its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.1450) per share and revenue of $7.8650 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Semler Scientific (NASDAQ:SMLR) last issued its quarterly earnings data on Monday, August 4th. The company reported $5.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $5.31. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.The firm had revenue of $8.22 million for the quarter, compared to analyst estimates of $8.10 million.

Semler Scientific Stock Performance

Shares of NASDAQ SMLR opened at $23.96 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58. The stock’s fifty day moving average price is $28.63 and its two-hundred day moving average price is $33.97. Semler Scientific has a one year low of $21.84 and a one year high of $81.56. The firm has a market cap of $362.75 million, a price-to-earnings ratio of 9.86 and a beta of 1.41.

Analysts Set New Price Targets

SMLR has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Semler Scientific in a report on Saturday. Maxim Group decreased their price objective on Semler Scientific from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, September 19th. Benchmark decreased their price objective on Semler Scientific from $101.00 to $86.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald cut their target price on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $74.25.

Institutional Trading of Semler Scientific

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its position in shares of Semler Scientific by 354.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,819 shares of the company’s stock valued at $70,000 after acquiring an additional 1,419 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Semler Scientific by 47.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,965 shares of the company’s stock valued at $144,000 after buying an additional 1,269 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Semler Scientific by 23.0% in the second quarter. JPMorgan Chase & Co. now owns 4,143 shares of the company’s stock valued at $160,000 after buying an additional 776 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Semler Scientific by 2,390.7% in the second quarter. BNP Paribas Financial Markets now owns 9,340 shares of the company’s stock valued at $362,000 after buying an additional 8,965 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in Semler Scientific in the second quarter valued at about $387,000. 49.37% of the stock is currently owned by institutional investors.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.